- Makes the only drug shown to reduce cold sore frequency and severity – competitors are treatment only & cannot prevent
- Successfully completed Phase 2 clinical trials with clear path to commercialization
- A single topical dose to the arm prevents outbreaks for over 4 months
- Clinical trials conducted at Harvard and Stanford
We are developing a drug that prevents cold sores or oral herpes outbreaks in people with frequent outbreaks. The drug has completed Phase 2 clinical trials and has worked great. It significantly reduces the number and severity of cold sores, with 1 topical dose to the arm (not the face or lip) every 3 months. It acts by boosting immune function.
We expect to have the drug approved and for sale in about 3 years, and then be generating $600 million annual sales, with a market capitalization $5 billion or more. No other opportunity in pharmaceuticals likely exists with (1) a market of this size, (2) a drug proven effective through Phase 2 clinicals trials, and (3) no other drug approved for the indication or even in clinical trials. These projections cannot be guaranteed.